New triple-drug combo aims to extend life in advanced liver cancer
NCT ID NCT06680258
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This phase 3 trial tests whether adding TPST-1120 to standard immunotherapy and anti-angiogenesis drugs helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned to receive either the triple combination or standard care. The study measures overall survival, progression-free survival, and tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.